CAMBRIDGE, Mass., May 31, 2018 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a leader in discovering and developing
targeted kinase medicines for patients with genomically defined
diseases, today announced its participation in the following
upcoming investor conferences:
- Jefferies 2018 Global Healthcare Conference in
New York, NY on Thursday, June 7, 2018 at 4:30 p.m. ET
- Goldman Sachs 39th Annual Global Healthcare
Conference in Rancho Palos Verdes,
CA on Tuesday, June 12, 2018
at 3:20 p.m. PT (6:20 p.m. ET)
A live webcast of each presentation will be available by
visiting the Investors section of Blueprint
Medicines' website at http://ir.blueprintmedicines.com. A
replay of each webcast will be archived on Blueprint
Medicines' website for 30 days following the presentation.
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other disease driven by the abnormal activation of kinases.
Blueprint Medicines is advancing multiple programs in clinical
development for subsets of patients with gastrointestinal stromal
tumors, hepatocellular carcinoma, systemic mastocytosis, non-small
cell lung cancer, medullary thyroid cancer and other advanced solid
tumors, as well as multiple programs in research and preclinical
development. For more information, please
visit www.blueprintmedicines.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-in-june-300657039.html
SOURCE Blueprint Medicines